Cargando…
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418092/ https://www.ncbi.nlm.nih.gov/pubmed/25992351 http://dx.doi.org/10.4103/2278-330X.155699 |
_version_ | 1782369436809822208 |
---|---|
author | Ali Shah, Syed Imran |
author_facet | Ali Shah, Syed Imran |
author_sort | Ali Shah, Syed Imran |
collection | PubMed |
description | Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen. |
format | Online Article Text |
id | pubmed-4418092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44180922015-05-19 Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer Ali Shah, Syed Imran South Asian J Cancer TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4418092/ /pubmed/25992351 http://dx.doi.org/10.4103/2278-330X.155699 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER Ali Shah, Syed Imran Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title | Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title_full | Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title_fullStr | Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title_full_unstemmed | Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title_short | Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
title_sort | emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer |
topic | TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418092/ https://www.ncbi.nlm.nih.gov/pubmed/25992351 http://dx.doi.org/10.4103/2278-330X.155699 |
work_keys_str_mv | AT alishahsyedimran emergingpotentialofparenteralestrogenasandrogendeprivationtherapyforprostatecancer |